TY - JOUR
T1 - Remission of Intermediate Uveitis
T2 - Incidence and Predictive Factors
AU - Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group
AU - Kempen, John H.
AU - Gewaily, Dina Y.
AU - Newcomb, Craig W.
AU - Liesegang, Teresa L.
AU - Kaçmaz, R. Oktay
AU - Levy-Clarke, Grace A.
AU - Nussenblatt, Robert B.
AU - Rosenbaum, James T.
AU - Sen, H. Nida
AU - Suhler, Eric B.
AU - Thorne, Jennifer E.
AU - Foster, C. Stephen
AU - Jabs, Douglas A.
AU - Payal, Abhishek
AU - Fitzgerald, Tonetta D.
AU - Joffe, Marshall M.
AU - Dreger, Kurt A.
AU - Pistilli, Maxwell
AU - Kothari, Srishti
AU - Khacharyan, Naira
AU - Artornsombudh, Pichaporn
AU - Hanish, Asaf
AU - Gangaputra, Sapna S.
AU - Begum, Hosne
AU - Daniel, Ebenezer
AU - Dunn, James P.
AU - Helzlsouer, Kathy J.
AU - Pujari, Siddharth S.
AU - Buchanich, Jeanine
AU - Washington, Terri L.
N1 - Funding Information:
Funding/Support: Supported primarily by National Eye Institute (Bethesda, MD, USA) Grant EY014943 (John H. Kempen). Additional support was provided by Research to Prevent Blindness (New York, NY, USA), the Paul and Evanina Mackall Foundation (New York, NY, USA), and the Lois Pope Life Foundation (New York, NY, USA). During the course of the study, John H. Kempen was a Research to Prevent Blindness James S. Adams Special Scholar Award recipient, Jennifer E. Thorne was a Research to Prevent Blindness Harrington Special Scholar Award recipient, and Douglas A. Jabs and James T. Rosenbaum were Research to Prevent Blindness Senior Scientific Investigator Award recipients. Eric B. Suhler receives support from the Veteran's Affairs Administration (Washington, DC, USA). Grace A. Levy-Clarke was previously supported by and Robert B. Nussenblatt and H. Nida Sen continue to be supported by intramural funds of the National Eye Institute. The funding organizations had no role in the design or conduct of this research. Financial disclosures: John H. Kempen has served as a consultant for AbbVie (North Chicago, IL, USA), Alcon (Fort Worth, TX, USA), Allergan (Dublin, Ireland), Can-Fite (Petah-Tikva, Israel), Clearside (Alpharetta, GA, USA), Lux Biosciences (Jersey City, NJ, USA), Roche (Basel, Switzerland), and Xoma (Berkeley, CA, USA), and is a grant recipient from EyeGate (Waltham, MA, USA). Eric B. Suhler has served as a consultant for Xoma, Santen (Osaka, Japan), and AbbVie, and has been a grant recipient from AbbVie, Xoma, and Bristol-Myers Squibb (New York, NY, USA). Jennifer E. Thorne has served as a consultant for AbbVie and Xoma. C. Stephen Foster has served as a consultant for Aldeyra (Lexington, MA, USA), Bausch & Lomb Surgical (Rochester, NY, USA), EyeGate, Novartis (Basel, Switzerland), pSivida (Watertown, MA, USA), and Xoma; has served as a paid speaker for Alcon and Allergan, and has grants or grants pending from Alcon, Aldeyra, Bausch & Lomb, Clearside Biomedical, Dompe (Milan, Italy), Icon (Dublin, Ireland), Novartis, Santen, Xoma, Aciont (Salt Lake City, UT, USA) and pSivida. Douglas A. Jabs has served as a consultant to Santen and AGTC (Covina, CA, USA). Oktay Ka?maz is employed by Allergan. The following authors have no financial disclosures: Dina Y. Gewaily, Craig W. Newcomb, Teresa L. Liesegang, R. Grace A. Levy-Clarke, Robert B. Nussenblatt, James T. Rosenbaum, H. Nida Sen, Abhishek Payal, and Tonetta D. Fitzgerald. All authors attest that they meet the current ICMJE criteria for authorship.
Funding Information:
Funding/Support: Supported primarily by National Eye Institute (Bethesda, MD, USA) Grant EY014943 (John H. Kempen). Additional support was provided by Research to Prevent Blindness (New York, NY, USA), the Paul and Evanina Mackall Foundation (New York, NY, USA), and the Lois Pope Life Foundation (New York, NY, USA). During the course of the study, John H. Kempen was a Research to Prevent Blindness James S. Adams Special Scholar Award recipient, Jennifer E. Thorne was a Research to Prevent Blindness Harrington Special Scholar Award recipient, and Douglas A. Jabs and James T. Rosenbaum were Research to Prevent Blindness Senior Scientific Investigator Award recipients. Eric B. Suhler receives support from the Veteran's Affairs Administration (Washington, DC, USA). Grace A. Levy-Clarke was previously supported by and Robert B. Nussenblatt and H. Nida Sen continue to be supported by intramural funds of the National Eye Institute. The funding organizations had no role in the design or conduct of this research. Financial disclosures: John H. Kempen has served as a consultant for AbbVie (North Chicago, IL, USA), Alcon (Fort Worth, TX, USA), Allergan (Dublin, Ireland), Can-Fite (Petah-Tikva, Israel), Clearside (Alpharetta, GA, USA), Lux Biosciences (Jersey City, NJ, USA), Roche (Basel, Switzerland), and Xoma (Berkeley, CA, USA), and is a grant recipient from EyeGate (Waltham, MA, USA). Eric B. Suhler has served as a consultant for Xoma, Santen (Osaka, Japan), and AbbVie, and has been a grant recipient from AbbVie, Xoma, and Bristol-Myers Squibb (New York, NY, USA). Jennifer E. Thorne has served as a consultant for AbbVie and Xoma. C. Stephen Foster has served as a consultant for Aldeyra (Lexington, MA, USA), Bausch & Lomb Surgical (Rochester, NY, USA), EyeGate, Novartis (Basel, Switzerland), pSivida (Watertown, MA, USA), and Xoma; has served as a paid speaker for Alcon and Allergan, and has grants or grants pending from Alcon, Aldeyra, Bausch & Lomb, Clearside Biomedical, Dompe (Milan, Italy), Icon (Dublin, Ireland), Novartis, Santen, Xoma, Aciont (Salt Lake City, UT, USA) and pSivida. Douglas A. Jabs has served as a consultant to Santen and AGTC (Covina, CA, USA). Oktay Kaçmaz is employed by Allergan. The following authors have no financial disclosures: Dina Y. Gewaily, Craig W. Newcomb, Teresa L. Liesegang, R. Grace A. Levy-Clarke, Robert B. Nussenblatt, James T. Rosenbaum, H. Nida Sen, Abhishek Payal, and Tonetta D. Fitzgerald. All authors attest that they meet the current ICMJE criteria for authorship.
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Purpose: To evaluate the incidence of remission among patients with intermediate uveitis; to identify factors potentially predictive of remission. Design: Retrospective cohort study. Methods: Involved eyes of patients with primary noninfectious intermediate uveitis at 4 academic ocular inflammation subspecialty practices, followed sufficiently long to meet the remission outcome definition, were studied retrospectively by standardized chart review data. Remission of intermediate uveitis was defined as a lack of inflammatory activity at ≥2 visits spanning ≥90 days in the absence of any corticosteroid or immunosuppressant medications. Factors potentially predictive of intermediate uveitis remission were evaluated using survival analysis. Results: Among 849 eyes (of 510 patients) with intermediate uveitis followed over 1934 eye-years, the incidence of intermediate uveitis remission was 8.6/100 eye-years (95% confidence interval [CI], 7.4–10.1). Factors predictive of disease remission included prior pars plana vitrectomy (PPV) (hazard ratio [HR] [vs no PPV] = 2.39; 95% CI, 1.42–4.00), diagnosis of intermediate uveitis within the last year (HR [vs diagnosis >5 years ago] =3.82; 95% CI, 1.91–7.63), age ≥45 years (HR [vs age <45 years] = 1.79; 95% CI, 1.03–3.11), female sex (HR = 1.61; 95% CI, 1.04–2.49), and Hispanic race/ethnicity (HR [vs white race] = 2.81; 95% CI, 1.23–6.41). Presence/absence of a systemic inflammatory disease, laterality of uveitis, and smoking status were not associated with differential incidence. Conclusions: Our results suggest that intermediate uveitis is a chronic disease with an overall low rate of remission. Recently diagnosed patients and older, female, and Hispanic patients were more likely to remit. With regard to management, pars plana vitrectomy was associated with increased probability of remission.
AB - Purpose: To evaluate the incidence of remission among patients with intermediate uveitis; to identify factors potentially predictive of remission. Design: Retrospective cohort study. Methods: Involved eyes of patients with primary noninfectious intermediate uveitis at 4 academic ocular inflammation subspecialty practices, followed sufficiently long to meet the remission outcome definition, were studied retrospectively by standardized chart review data. Remission of intermediate uveitis was defined as a lack of inflammatory activity at ≥2 visits spanning ≥90 days in the absence of any corticosteroid or immunosuppressant medications. Factors potentially predictive of intermediate uveitis remission were evaluated using survival analysis. Results: Among 849 eyes (of 510 patients) with intermediate uveitis followed over 1934 eye-years, the incidence of intermediate uveitis remission was 8.6/100 eye-years (95% confidence interval [CI], 7.4–10.1). Factors predictive of disease remission included prior pars plana vitrectomy (PPV) (hazard ratio [HR] [vs no PPV] = 2.39; 95% CI, 1.42–4.00), diagnosis of intermediate uveitis within the last year (HR [vs diagnosis >5 years ago] =3.82; 95% CI, 1.91–7.63), age ≥45 years (HR [vs age <45 years] = 1.79; 95% CI, 1.03–3.11), female sex (HR = 1.61; 95% CI, 1.04–2.49), and Hispanic race/ethnicity (HR [vs white race] = 2.81; 95% CI, 1.23–6.41). Presence/absence of a systemic inflammatory disease, laterality of uveitis, and smoking status were not associated with differential incidence. Conclusions: Our results suggest that intermediate uveitis is a chronic disease with an overall low rate of remission. Recently diagnosed patients and older, female, and Hispanic patients were more likely to remit. With regard to management, pars plana vitrectomy was associated with increased probability of remission.
UR - http://www.scopus.com/inward/record.url?scp=85027949372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027949372&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2015.12.034
DO - 10.1016/j.ajo.2015.12.034
M3 - Article
C2 - 26772874
AN - SCOPUS:85027949372
SN - 0002-9394
VL - 164
SP - 110-117.e2
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -